116
Participants
Start Date
March 16, 2023
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2029
VGA039
Single doses of VGA039
Placebo
Single doses of Placebo
VGA039
Multiple doses of VGA039
RECRUITING
Royal Brisbane & Women's Hospital, Queensland Haemophilia Centre, Herston
RECRUITING
Hemophilia Center of Western PA, Pittsburgh
RECRUITING
Science 37, Inc., Morrisville
RECRUITING
Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Atlanta
RECRUITING
Vanderbilt University Medical Center, Nashville
RECRUITING
Versiti Comprehensive Center for Bleeding Disorders, Milwaukee
RECRUITING
University of Texas Southwestern, Dallas
RECRUITING
University of Colorado School of Medicine, Aurora
RECRUITING
Orthopedic Institute for Children (UCLA), Los Angeles
RECRUITING
UC Davis Medical Center, Sacramento
RECRUITING
Washington Center for Bleeding Disorders, Seattle
RECRUITING
K J Somaiya Super Speciality Hospital & Research Centre, Sion
COMPLETED
Medical University of Vienna, Vienna
RECRUITING
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg
RECRUITING
Imperial College Healthcare NHS Trust- Queen Charlotte's & Chelsea Hospital, London
RECRUITING
Centro de Hemoterapia e Hematologia do Rio de Janeiro HEMORIO, Rio de Janeiro
RECRUITING
Hemocentro Unicamp, Campinas
RECRUITING
Hospital das Clinicas - USP Endereco, São Paulo
RECRUITING
Hamilton Health Sciences Corporation, Hamilton
RECRUITING
Queens University, Kingston
RECRUITING
St. Michaels Hospital, Toronto
RECRUITING
Queen Elizabeth Hospital Birmingham, Birmingham
RECRUITING
University Hospital Southampton NHS Foundation Trust, Southampton
RECRUITING
Royal Free Hospital, London
RECRUITING
Royal London Hospital, Clinical Haematology Research, Whitechapel
Vega Therapeutics, Inc
INDUSTRY